Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Endocrine-Related Cancer|August 17, 2016
Androgen receptor signaling pathways as a target for breast cancer treatmentElisabetta Pietri, Vincenza Conteduca, Daniele Andreis, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2017
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancerAndrea Rocca, Lorenzo Cecconetto, Alessandro Passardi, et al.
Translational Oncology|June 12, 2018
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?Giuseppe Bronte, Sara Bravaccini, Sara Ravaioli, et al.
Therapeutic Advances in Medical Oncology|March 23, 2023
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cureFilippo Merloni, Michela Palleschi, Chiara Casadei, et al.
Science Signaling|December 19, 2023
A noncanonical IRAK4-IRAK1 pathway counters DNA damage-induced apoptosis independently of TLR/IL-1R signalingYuanyuan Li, Richa B Shah, Samanta Sarti, et al.
Heart (British Cardiac Society)|January 26, 2013
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factorsAlberto Farolfi, Elisabetta Melegari, Michele Aquilina, et al.
BMC Cancer|March 29, 2018
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?Giuseppe Bronte, Andrea Rocca, Sara Ravaioli, et al.
The Oncologist|August 7, 2015
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerValentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, et al.
Oncogene|January 22, 2019
Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanomaMarianna Vitiello, Monica Evangelista, Nicole Di Lascio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, Maria V Dieci, Gaia Griguolo, et al.
Pageof 5